Dr. Thompson on the Rationale for the BRUIN Study in Richter Transformation

Video

In Partnership With:

Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation. 

Meghan Thompson, MD, third-year fellow, Hematology and Medical Oncology, Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase 1/2 BRUIN study (NCT03740529) in patients with Richter transformation. 

Richter transformation is a rare, but serious complication that arises in a small subgroup of patients with CLL, Thompson says. Moreover, the disease can transform into a more aggressive lymphoma, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, Thompson adds. Patients with Richter transformation are considered high risk and have an estimated overall survival ofbetween 3 and 11 months, Thompson explains.

Moreover, the standard of care treatment is not clear for these patients, Thompson continues. However, the BRUIN study evaluated a novel approach to treating patients with Richter transformation with pirtobrutinib (LOXO-305), Thompson concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Martin H. Voss, MD, an expert on renal cell carcinoma
Laurence Albigès, MD, PhD, an expert on renal cell carcinoma
A panel of 4 experts on hematologic malignancies